Fidson Healthcare Ltd.
NNSENG:FIDSON83.50
NGN
0.00
(0.00%)
ISIN
NGFIDSON0006
Return %
Stock
S&P 500
1Y
102.46
14.20
3Y
488.60
81.12
5Y
1,431.79
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Abiola A. Adebayo
- Full Time Employees
- 732
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Lagos Nigeria
- IPO Date
- Jun 4, 2008
- Website
- fidson.com
- Similar Companies
- Business
- Fidson Healthcare Plc manufactures, markets, and distributes pharmaceutical and healthcare products across Nigeria and the broader West African region. The company operates through three principal business segments: Over-the-Counter (OTC), Ethical Products, and Consumer Healthcare. Its diversified product portfolio encompasses anti-infective and antibacterial treatments; anti-malarials; cardiovascular and antihypertensive agents; central nervous system therapies; gastrointestinal medications; analgesics, antipyretics, and anti-inflammatory drugs; endocrinology formulations; dermatological and topical treatments; ophthalmic solutions; and nutritional supplements, including vitamins and amino acid formulations. Fidson produces pharmaceutical formulations in multiple dosage forms, such as tablets, capsules, oral liquids, syrups, suspensions, dry powders, ointments, creams, small-volume injectables, and large-volume parenteral infusions, with commercial brands including Astymin, Ciprotab, Co-Arthemed, Tribotan, Tuxil, Ferotop, and Asmabu. In addition to proprietary pharmaceutical manufacturing, the company provides contract manufacturing services, third-party distribution and logistics, institutional healthcare procurement supply, and technical collaboration services with international pharmaceutical partners. In recent corporate developments, Fidson entered into a strategic cooperation agreement with China-based Jiangsu Aidea Pharma, Nanjing PharmaBlock, and the China-Africa Development Fund to establish a joint venture manufacturing facility in Nigeria dedicated to local production of advanced antiretroviral therapeutics; formed a strategic healthcare partnership with Japan-based Ohara Pharmaceutical to advance specialized medicine accessibility in Africa; secured financing support through the European Investment Bank and Bank of Industry healthcare credit facility to scale local pharmaceutical infrastructure; completed a ₦21 billion rights issue to fund production capacity expansion, technological upgrades, and regional market penetration; and received a ₦9.99 billion federal government contract to scale domestic antiretroviral medication output. Fidson Healthcare Plc was founded in 1995 and is headquartered in Lagos, Nigeria, with primary Current Good Manufacturing Practice-compliant production facilities located in Ota, Ogun State.